Lineage Cell Therapeutics (LCTX) Corporate presentation summary

Mission and platform overview

• Focuses on directed differentiation and transplant of allogeneic cells to treat serious conditions.

• AlloSCOPET platform enables scalable, consistent, off-the-shelf cell therapies using pluripotent stem cells.

• Proprietary process allows production of over 200 human cell types, with validated manufacturing and quality controls.

• Holds approximately 375 issued and pending patents, supporting a broad pipeline.

Partnerships and collaborations

• Global partnership with Roche/Genentech for OpRegen, with up to $670M in milestones and double-digit royalties.

• Preclinical collaboration with William Demant Invest for Resonance, with up to $12M in funding.

• Additional partnerships include CIRM for grants and Factor Bioscience for gene editing.

Clinical pipeline and programs

• Two active clinical trials: OpRegen for dry AMD and OPC1 for spinal cord injury.

• OpRegen: Phase 1/2a completed, showing sustained visual and anatomical improvements up to 36 months, especially in patients with extensive bleb coverage.

• OPC1: Over 30 patients treated, with durable motor improvements and no serious cell-related adverse events; ongoing DOSED study for new delivery system.

• Additional preclinical programs include Resonance (hearing loss), COR1 (corneal disease), ILT1 (type 1 diabetes), and PNC1 (vision loss/retinitis pigmentosa).